Jian-Guo Zhao1, Ling Zhang2, Xiao-Jun Xiang2, Feng Yu2, Wan-li Ye1, Dong-Ping Wu1, Jian Fang Wang1, Jian-Ping Xiong2
1Department of Oncology, Shaoxing People’s Hospital ,Shaoxing Hospital of Zhejiang University, Shaoxing 312000,China;
2Department of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, Nanchang, 330006, China.
Retraction note to: JBUON 2016;21(3):609-617; PMID: 27569081
Following the publication of this article [1], readers drew to our attention that part of the data was unreliable: Figures of this article appeared in other articles (by totally different authors). The authors were requested to provide the raw data and were also asked for an explanation to account for these concerns, however, the Editorial Office hasn’t received any reasonable reply. To make the readers alert, we published an Expression of Concern for this article months ago. Now we completed the investigation and decided to retract this article. Authors were informed of the retraction. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.
References
1. Zhao JG, Zhang L, Xiang XJ et al. Amarogentin secoiridoid inhibits in vivo cancer cell growth in xenograft mice model and induces apoptosis in human gastric cancer cells (SNU-16) through G2/M cell cycle arrest and PI3K/Akt signalling pathway. JBUON 2016;21:609-17.
The original article can be found online at: https://www.jbuon.com/archive/21-3-609.pdf
Full Text: PDF